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Abstract: This study aims to investigate potential diabetic retinopathy (DR) risk factors by 
evaluating the circulating levels of pentosidine, soluble receptor for advanced glycation 
end-product (sRAGE), advanced oxidation protein product (AOPP) as well as glutathione 
peroxidase (GPx) and superoxide dismutase (SOD) activities in DR patients. A total of  
235 healthy controls, 171 type 2 diabetic without retinopathy (DNR) and 200 diabetic 
retinopathy (DR) patients were recruited. Plasma was extracted for the estimation of 
pentosidine, sRAGE, AOPP levels and GPx activity whereas peripheral blood mononuclear 
cells were disrupted for SOD activity measurement. DNR and DR patients showed 
significantly higher levels of plasma pentosidine, sRAGE and AOPP but lower GPx and 
SOD activities when compared to healthy controls. The sRAGE/pentosidine ratio in DR 
patients was significantly lower than the ratio detected in DNR patients. Proliferative DR 
patients had significantly higher levels of plasma pentosidine, sRAGE, AOPP and 
sRAGE/pentosidine ratio than non-proliferative DR patients. High HbA1c level, long 
duration of diabetes and low sRAGE/pentosidine ratio were determined as the risk factors 
for DR. This study suggests that sRAGE/pentosidine ratio could serve as a risk factor 
determinant for type 2 DR as it has a positive correlation with the severity of DR. 
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1. Introduction 
Diabetes mellitus (DM) is one of the top four most conspicuous non communicable diseases that 
lead to death worldwide [1]. The International Diabetes Federation predicts that South East Asia region 
would have the highest prevalence of DM in 2025 [2] mainly due to the population growth and 
increase in the rate of obesity. The worldwide rise in DM prevalence will inevitably be accompanied 
by the increased incidence of irreversible DM associated complications which includes diabetic 
retinopathy (DR). DR is the greatest fear among DM related ocular complications as it can lead to 
blindness and disability [3]. The prevalence of DR among type 2 DM patients in Malaysia is on the 
rise, with 10% after 5 years and 42.9% after 10 years of diagnosis [4]. 
Oxidative stress is an acknowledged pathogenic mechanism in complications of DM. Hyperglycemia 
stimulates the increased production of reactive oxygen species through several mechanisms including 
glucose auto-oxidation, redox imbalance, advanced glycation end products (AGE)-receptor interaction, 
oxidative phosphorylation, lipooxygenase, cytochrome P450 monooxygenase and nitric oxide  
synthase [5,6]. The production of reactive oxygen species leads to the depletion of both enzymatic and 
non-enzymatic antioxidants which inevitably results in cellular damage [7]. Numerous studies have 
shown that treatment with antioxidants ameliorates complications of DM [8]. The DM environment 
causes proteins to undergo sequential non-enzymatic glycation with reducing sugar to form AGE [9]. 
Pentosidine is one of the well characterized AGEs. The formation of AGE is accompanied by 
oxidative, radical-generating reactions. There is substantial evidence to support that the binding of 
AGE to its receptor (RAGE) is involved in the development of microvascular complications [9,10]. 
Soluble RAGE (sRAGE), a RAGE isoform lacking the transmembrane domain, is a recently 
discovered inhibitor of AGE-RAGE mediated pathological effects [11]. It was shown to confer 
protection on blood vessels against AGE-RAGE mediated microvascular damage in DM [12,13]. 
However, the association between sRAGE and other oxidative-glycation biomarkers such as 
pentosidine and advanced oxidation protein product (AOPP) in DR patients are still unclear.  
This study was aimed to investigate potential clinical risk factors for DR by evaluating the 
relationship between selected parameters in the oxidative system, mainly the circulating pentosidine, 
sRAGE, AOPP, glutathione peroxidase (GPx) and superoxide dismutase (SOD) in DR.  
2. Results 
The demographic data of healthy controls, DNR, DR, NPDR and PDR patients are stated in Table 1. 
The patients (DNR and DR) had significantly (p < 0.05) higher levels of glycated haemoglobin 
(HbA1c), total cholesterol, LDL-C and systolic blood pressure (SBP), lower diastolic blood pressure 
(DBP) and HDL-C/LDL-C ratio when compared to the healthy controls. Besides, the number of 
hypertensive subjects in the patient groups was significantly higher than in the healthy controls. 
Comparisons between DNR and DR patients showed significant differences (p < 0.05) in the levels of 
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HbA1c and total cholesterol, estimated glomerular filtration rate, duration of DM and the number of 
smokers. No significant difference was found for most of the parameters in NPDR and PDR patients 
except for age, HDL-C, triglycerides, SBP and retinopathy duration. PDR patients had significantly 
higher triglycerides level and SBP, longer duration of DR but had significantly lower HDL-C level and 
number of subjects who received antihyperglycemic treatment when compared to NPDR patients. 
Table 1. Demographic profiles of the healthy controls, DNR, DR, NPDR and PDR patients. 
Demography 
Ctrl  
(n = 235) 
DNR  
(n = 171) 
DR  
(n = 200) 
NPDR  
(n = 125) 
PDR  
(n = 75) 
Gender (male/female) 134/101 100/71 110/90 67/58 43/32 
Races (Malay/Chinese/Indian) (n) 106/90/39 63/28/80 a 70/47/83 a 40/29/56 30/18/27 
Age (years) 57.1 ± 4.1 59.2 ± 9.6 57.2 ± 9.8 59.0 ± 9.9 53.1 ± 8.8 c 
BMI (kg/m2) 25.6 ± 4.8 27.2 ± 4.4 26.3 ± 5.0 26.2 ± 4.5 26.6 ± 5.9 
HbA1c (%) 5.6 ± 0.4 7.9 ± 1.8 a 8.9 ± 2.1 a,b 9.1 ± 2.3 8.5 ± 1.8 
Total cholesterol (mmol/L) 3.8 ± 0.6 4.5 ± 1.0 a 4.8 ± 1.5 a,b 4.8 ± 1.4 4.9 ± 1.5 
Triglyceride (mmol/L) 1.8 ± 1.3 1.6 ± 0.7 1.7 ± 1.0 1.6 ± 0.9 2.0 ± 1.1 c 
HDL-C (mmol/L) 1.0 ± 0.3 1.2 ± 0.3 a 1.2 ± 0.3 a 1.3 ± 0.3 1.1 ± 0.3 c 
LDL-C (mmol/L) 2.1 ± 0.5 2.5 ± 0.9 a 2.8 ± 1.2 a 2.8 ± 1.2 2.9 ± 1.3 
HDL-C/LDL-C ratio 0.6 ± 0.2 0.5 ± 0.2 a 0.5 ± 0.2 a 0.5 ± 0.2 0.4 ± 0.2 
SBP (mmHg) 124.0 ± 8.0 136.5 ± 19.5 a 139.3 ± 22.4 a 136.6 ± 21.4 146.6 ± 23.0 c 
DBP (mmHg) 83.0 ± 7.0 79.0 ± 10.5 a 78.4 ± 13.1 a 77.2 ± 11.9 81.6 ± 15.6 
ALT (IU/L) – 37.8 ± 17.5 36.8 ± 24.6 38.1 ± 27.0 33.9 ± 18.3 
AST (IU/L) – 22.0 ± 14.0 22.8 ± 16.4 22.7 ± 17.2 23.0 ± 15.0 
Creatinine (μmol/L) – 94.9 ± 13.4 98.1 ± 12.8 90.0 ± 15.4 100.1 ± 13.6 
eGFR (ml/min/1.73m2) – 82.6 ± 9.6 90.2 ± 10.4 b 92.2 ± 7.3 88.3 ± 12.7 
Diabetes duration (years) – 10.4 ± 7.9 15.7 ± 9.1 b 16.3 ± 9.4 14.6 ± 8.2 
Retinopathy duration d (years)  – – 5.0 ± 3.6 3.4 ± 2.0 7.4 ± 4.3 c 
Current smoker (n) 43 29 13 a,b 7 6 
Hypertension (n) 11 104 a 119 a 80 39 
Antihyperglycemic treatment e (n) 0 107 a 130a 93 37 c 
Duration of antihyperglycemic 
treatment (years) 
– 9.5 ± 5.5 11.5 ± 7.5 9.9 ± 3.6 11.0 ± 5.2 
Antihypertensive treatment f (n) 0 104 a 119 a 79 40 
Duration of antihypertensive 
treatment (years) 
– 7.0 ± 3.5 8.5 ± 4.0 7.7 ± 2.8 8.3 ± 3.5 
Notes: Data were expressed as mean ± SD unless otherwise indicated. Dichotomous variables are given in absolute 
numbers. a p < 0.05 versus healthy control; b p < 0.05 versus DNR; c p < 0.05 versus NPDR; d Period derived from the 
time when retinopathy complication was first diagnosed in the patients; e Oral medications and insulin; f Inclusive of 
angiotensin-converting enzyme inhibitors, angiotensin II type I receptor antagonists, calcium channel blockers and 
diuretics; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BMI = body mass index; Ctrl = healthy controls; 
DBP= diastolic blood pressure; DNR = diabetic non-retinopathy; DR = diabetic retinopathy; eGFR = estimated glomerular 
filtration rate; HbA1c = glycated haemoglobin; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein 
cholesterol; NPDR = non-proliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy; SBP = systolic 
blood pressure. 
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In this study, the patients (DNR and DR) showed significant elevation of plasma pentosidine, 
sRAGE and AOPP levels as compared to the healthy controls (Figure 1). However, significantly lower 
sRAGE/pentosidine ratio, plasma GPx and SOD activities in the PBMC were present in the patients 
(DNR and DR). Interestingly, DR patients showed significantly higher levels of plasma sRAGE and 
AOPP but lower sRAGE/pentosidine ratio when compared to DNR patients. Comparison between 
NPDR and PDR patients showed that PDR patients had significantly higher levels of plasma 
pentosidine, sRAGE, AOPP and sRAGE/pentosidine ratio (Figure 1). 
Figure 1. The measured biochemical parameters in Ctrl (n = 235), DNR (n = 171), DR  
(n = 200), NPDR (n = 125) and DR (n = 75) patients. Data were expressed as mean ± SD. 
AOPP = advanced oxidation protein product; Ctrl = healthy controls; DNR = diabetic  
non-retinopathy; DR = diabetic retinopathy; GPx = glutathione peroxidase; SOD = superoxide 
dismutase; sRAGE = soluble form of RAGE. a1 p < 0.05, a2 P < 0.01, a3 p < 0.001 versus 
healthy controls; b1 p < 0.05, b2 p < 0.01, b3 p < 0.001 versus DNR; c1 p < 0.05,  
c2 p < 0.01 versus NPDR. 
 
The correlation results shown in this study (Tables 2 and 3) were weak (r < 0.5) but significant  
(p < 0.05). The risk factor for DR among type 2 DM patients was investigated using the logistic 
regression model. Parameters such as age, smoker, HbA1c level, DM duration, total cholesterol level, 
LDL-C level, SOD activity and sRAGE/pentosidine ratio were significant determinants for DR  
(Table 4). However, after adjusting for age, gender and metabolic risk factors (BMI, HbA1c, duration 
of DM), HbA1c level (OR = 1.20, 95% CI = 1.00–1.44, p = 0.046), duration of DM (OR = 1.08,  
95% CI = 1.04–1.13, p = 0.000) and sRAGE/pentosidine ratio (OR = 0.08, 95% CI = 0.01–0.98, p = 0.048) 
still remained significant. 
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Table 2. Linear correlation analysis between AOPP, pentosidine, sRAGE levels and 
several biochemical parameters in DNR patients (n = 171). 
Variables 
AOPP (μmol/L) Pentosidine (ng/mL) sRAGE (pg/mL) 
r p value r p value r p value 
HbA1c (%) 0.20 0.017 0.07 NS 0.03 NS 
Total cholesterol (mmol/L) 0.19 0.026 −0.05 NS −0.17 0.047 
Triglycerides (mmol/L) 0.24 0.004 −0.11 NS −0.10 NS 
GPx (U/L) −0.17 0.043 −0.31 0.0002 −0.19 0.028 
SOD (U/mg) −0.20 0.015 −0.19 0.027 0.02 NS 
Diabetes duration (years) 0.13 NS 0.31 0.0002 0.25 0.003 
AOPP = advanced oxidation protein product; DNR = diabetic non-retinopathy; GPx = glutathione peroxidase;  
HbA1c = glycated haemoglobin; NS = not significant; r = Pearson’s coefficient; SOD = superoxide dismutase;  
sRAGE = soluble form of RAGE. 
Table 3. Linear correlation analysis between AOPP, pentosidine, sRAGE levels and 
several biochemical parameters in DR patients (n = 200). 
Variables 
AOPP (μmol/L) Pentosidine (ng/mL) sRAGE (pg/mL) sRAGE/pentosidine ratio 
r p value r p value r p value r p value 
HbA1c (%) 0.08 NS 0.18 0.021 −0.10 NS −0.23 0.003 
Total cholesterol (mmol/L) 0.10 NS 0.05 NS 0.02 NS −0.04 NS 
Triglycerides (mmol/L) 0.30 0.0002 −0.10 NS 0.11 NS −0.08 NS 
GPx (U/L) −0.35 <0.0001 −0.26 0.0006 −0.31 <0.0001 −0.05 NS 
SOD (U/mg) −0.16 0.033 −0.21 0.008 −0.03 NS 0.02 NS 
Diabetes duration (years) 0.06 NS 0.18 0.013 0.15 NS − 0.20 0.004 
Retinopathy duration (years) 0.11 NS 0.12 NS −0.15 0.043 0.48 0.010 
AOPP = advanced oxidation protein product; DR = diabetic retinopathy; GPx = glutathione peroxidase; 
HbA1c = glycated haemoglobin; NS = not significant; r = Pearson’s coefficient; SOD = superoxide dismutase; 
sRAGE = soluble form of RAGE. 
Table 4. Risk factors for DR in type 2 DM patients (n = 371) by logistic regression.  
Characteristics 
Unadjusted model Adjusted model a 
OR (95% CI) p value OR (95% CI) p value 
Age (years) 0.98 (0.96–1.00) 0.022 0.96 (0.93–1.00) 0.052 
Gender                Female 1.00 (reference) – – – 
                            Male 0.87 (0.58–1.31) 0.511 – – 
Race                    Malay  1.00 (reference) – – – 
                            Chinese 1.30 (0.74–2.30) 0.365 – – 
                            Indian   0.79 (0.50–1.23) 0.297 – – 
Smoker                No 1.00 (reference) – – – 
                             Yes 0.51 (0.30–0.87) 0.013 0.40 (0.15–1.03) 0.057 
Hypertension       No 1.00 (reference) – – – 
                             Yes 0.79 (0.49–1.28) 0.347 – – 
BMI (kg/m2) 0.96 (0.92–1.01) 0.099 – – 
SBP (mmHg) 1.01 (1.00–1.02) 0.274 – – 
DBP (mmHg) 1.00 (0.98–1.02) 0.736 – – 
Total cholesterol (mmol/L) 1.25 (1.04–1.49) 0.018 1.46 (0.76–2.79) 0.251 
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Table 4. Cont. 
Characteristics 
Unadjusted model Adjusted model a 
OR (95% CI) p value OR (95% CI) p value 
Triglyceride (mmol/L) 1.25 (0.96–1.63) 0.100 – – 
HDL-C (mmol/L) 1.02 (0.53–1.95) 0.952 – – 
LDL-C (mmol/L) 1.25 (1.01–1.54) 0.045 0.68 (0.33–1.42) 0.308 
ALT (IU/L) 1.00 (0.99–1.01) 0.998 – – 
AST (IU/L) 1.00 (0.99–1.02) 0.615 – – 
Diabetes duration (years) 1.08 (1.05–1.11) 0.000 1.08 (1.04–1.13) 0.000 
HbA1c (%) 1.34 (1.18–1.53) 0.000 1.20 (1.00–1.44) 0.046 
GPx (U/L) 1.00 (1.00–1.01) 0.586 – – 
SOD (U/mg) 7.28 (4.42–17.57) 0.000 3.48 (0.55–22.18) 0.187 
AOPP (μmol/L) 1.00 (1.00–1.01) 0.212 – – 
Pentosidine (ng/mL) 0.99 (0.97–1.01) 0.168 – – 
sRAGE (pg/mL) 1.00 (1.00–1.01) 0.090 – – 
sRAGE/pentosidine ratio 0.08 (0.02–0.37) 0.001 0.08 (0.01-0.98) 0.048 
a Adjusted for age, gender and metabolic risk factors (BMI, HbA1c and DM duration); ALT = alanine aminotransferase; 
AOPP = advanced oxidation protein product; AST = aspartate amino transferase; BMI = body mass index; CI = confidence 
interval; DBP = diastolic blood pressure; DNR = diabetic non-retinopathy; DR = diabetic retinopathy; GPx = glutathione 
peroxidase; HbA1c = glycated haemoglobin; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein 
cholesterol; OR = odd ratio; SOD = superoxide dismutase; sRAGE = soluble form of RAGE; SBP = systolic blood pressure. 
3. Discussion 
Soluble RAGE (sRAGE), a RAGE isoform lacking the transmembrane domain, is a recently 
discovered naturally occurring inhibitor of AGE-RAGE mediated pathological effects [11]. Conflicting 
results on the sRAGE level in DM patients have been reported previously [14,15]. In this study, 
antihypertensive treatment did not significantly affect the sRAGE level in the patients (data not shown) 
which is in accordance with a previous report [16]. Therefore, it is unlikely that such treatment could 
confound the present results although certain antihypertensive medications have been shown to 
modulate sRAGE level in human subjects [17]. Our study shows that sRAGE level and DM duration 
in DNR patients were positively correlated (Table 2). The increased plasma sRAGE level in DNR and 
DR patients could be viewed as a protective reaction to counterbalance, at least partly, the elevated 
plasma pentosidine level. However, the regulatory mechanisms that are responsible for the increased 
sRAGE are unknown and remain to be elucidated. Due to the presence of intracellular glycation in DM 
and the fact that pentosidine is not a major ligand for RAGE [17], the increased circulating level of 
plasma sRAGE would not likely reduce the rate of DR progression in type 2 DM patients.  
Interestingly, DR patients had a significantly lower sRAGE/pentosidine ratio than DNR patients. It 
should be noted that sRAGE level was markedly elevated in DR patients whereas an increase in 
pentosidine level was observed in all DM patients, independent of retinopathy complication. PDR 
patients with longer duration of retinopathy had significantly higher sRAGE/pentosidine ratio than 
NPDR patients and sRAGE/pentosidine ratio was positively correlated with retinopathy duration 
(Table 3). Thus, high sRAGE/pentosidine ratio among the DR patients may be used to predict the 
severity of DR. With the finding of sRAGE/pentosidine ratio as a significant determinant for DR 
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(Table 4), this study suggests that sRAGE/pentosidine ratio could serve as a risk factor for DR among 
type 2 DM patients. In contrast to a previous report [18], pentosidine level was not significantly 
different between DR and DNR patients in this study. This could be explained by the variation in 
patient populations [19]. Our patients were of type 2 DM, older and had higher HbA1c level when 
compared to the patients recruited in a previous study [18]. The patient groups (DNR and DR) in this 
study consisted of a significant number of Indian subjects when compared to the healthy controls as it 
was not possible to obtain significant healthy Indian volunteers in the age-group of interest. 
Nevertheless, the measured parameters in the healthy volunteers from various ethnic groups did not 
show significant differences. 
Oxidative stress is widely recognized as the key component in the pathogenesis of diabetic 
complications. Human bodies are constantly protected against excessive oxidative stress by a complex 
set of enzymatic and non-enzymatic antioxidant systems. Both enzymatic antioxidants superoxide 
dismutase (SOD) and glutathione peroxidase (GPx) are involved in the metabolism of superoxide and 
hydrogen peroxide respectively [20]. The significant decrease of GPx and SOD activity in DNR and 
DR patients found in this study provides further evidence on the imbalance of antioxidant system in 
subjects with DM complications [21]. Numerous stable end products of oxidative stress have been 
identified and these include the AOPP. AOPP also serves as a biomarker for inflammation [22]. The 
elevated levels of plasma AOPP and pentosidine in DNR and DR patients as well as the significant 
positive correlation between pentosidine and HbA1c, DM duration in DR patients (Table 3) support the 
presence of oxidative stress in DR patients.  
In addition, the negative correlations found between enzymatic antioxidant activity (GPx and SOD) 
and circulating oxidative-glycation products (AOPP and pentosidine) in both DNR and DR patients in 
this study (Tables 2 and 3) confirmed the inverse relationship between the antioxidant status and 
hyperglycemia-dependent cellular changes in patients with type 2 DM. Other than HbA1c level, AOPP 
was also positively correlated with total cholesterol level in DNR patients and triglycerides level in 
both the patient groups (Tables 2 and 3). This finding supports the fact that hyperglycemia is not the 
only causal factor for exacerbating oxidative damage in DR patients. The generation of superoxide via 
mitochondrial electron transport chain [19] and the activation of NADPH-oxidase in monocytes 
triggered by AOPP [23] could also contribute to oxidative damage in DR.  
N-carboxymethyl-lysine (CML), an oxidatively formed AGE has been previously shown to be 
present both as a regular constituent in non-DM retinas and in neuroglial vasculature of DM patients [24] 
and it has been shown to be associated with proliferative DR and macular oedema [25]. Meanwhile 
pentosidine is a non-oxidatively formed AGE, which has specificity to microvasculature and the entire 
retina of DM patients while co-localizing with the expression of RAGE [24]. The accumulation of 
AGE in DR patients could exert its toxic effect through several mechanisms such as by modifying the 
protein’s tertiary structure through cross-linking, impairing receptor recognition and altering enzymatic 
activity [19]. The sustained AGE-RAGE interaction in DR patients could activate pro-inflammatory 
pathways by inducing the expression of cytokines and adhesive molecules [26], all of which could 
affect the blood-retinal barrier. AOPP shares common biological effect exerted by AGE, including 
interaction with RAGE [26] which ultimately leads to neovascularisation that could result in DR.  
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4. Experimental Section  
4.1. Ethic Statement 
Written informed consent was obtained from each subject prior to blood collection. The study was 
performed in adherence to the principles of the Declaration of Helsinki and approved by the Medical 
Ethics Review Committee of University Malaya Medical Centre, Malaysia (Institutional Review Board 
Number: 744.12). 
4.2. Study Population 
The study subjects were patients with type 2 DM referred to the Ophthalmology clinic between 
September 2009 and December 2011 at University Malaya Medical Centre (UMMC), Malaysia. DM 
was diagnosed according to the World Health Organization criteria. Type 1 DM and type 2 DM 
patients with complications other than retinopathy were excluded from the study. The blood creatinine 
level and estimated glomerular filtration rate in all the patients were examined to exclude those with 
possible nephropathy complication. Subjects with previous history of chronic inflammatory diseases, 
who were on anti-inflammatory drug treatment and antioxidant supplements were also excluded as 
these factors would affect the oxidative stress related parameters. A total of 371 unrelated Type 2 DM 
patients [171 patients without retinopathy (DNR) and 200 with retinopathy (DR)] (210 men,  
161 women) aged 58.2 ± 9.7 years (mean ± SD; range, 40 to 78 years), were recruited. Detailed 
medical and ophthalmologic histories as well as socio-demographic factors and lifestyle variables of 
each patient were obtained.  
All the patients recruited in this study underwent a complete eye examination that included dilated 
retinal examination and 7-field stereoscopic Diabetic Retinopathy Study retinal photography [27]. For 
DR patients, the color fundus photographs were graded for DR severity in a masked fashion by two 
independent ophthalmologists at University of Malaya Eye Research Centre, Kuala Lumpur. The 
modified Early Treatment of Diabetic Retinopathy Study Airlie House classification of DR was used 
to grade the retinopathy into the following categories: mild non-proliferative retinopathy (mild NPDR), 
moderate non-proliferative retinopathy (moderate NPDR), severe non-proliferative retinopathy (severe 
NPDR) and proliferative retinopathy (PDR) [28,29]. Among the DR patients, 26 had mild NPDR,  
85 moderate NPDR, 14 severe NPDR and 75 PDR.  
The healthy controls were blood-donor volunteers, consisting of 235 subjects (134 men, 101 women) 
aged 57.1 ± 4.1 years (mean ± SD; range, 45 to 65 years). They were recruited from multiple blood 
donation campaigns held between January 2010 and October 2010 in Malaysia. Their blood profiles 
were examined by the attending doctors through clinical and biochemical methods.  
4.3. Sample Collection and Preparation 
Six mL of blood was collected from patients and control subjects. Three mL of blood was used for 
glycated haemoglobin (HbA1c), total cholesterol, high-density lipoprotein (HDL-C), low-density 
lipoprotein (LDL-C), triglycerides, creatinine, alanine amino transferase (ALT) and aspartate amino 
transferase (AST) measurement at the Clinical Diagnostic Laboratory, University Malaya Medical 
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Centre. The whole blood samples were centrifuged for 15 min at 1000× g. The plasma was extracted 
and stored at −80 °C for pentosidine enzyme-linked immunosorbent assay (ELISA), sRAGE ELISA, 
GPx and AOPP assays. Subsequently, the cell sediments of EDTA blood tubes were reconstituted with 
isotonic phosphate buffer saline solution. The peripheral blood mononuclear cells (PBMC) were isolated 
as previously described [30], based on density gradient centrifugation method. PBMCs (2 × 106 cells) 
were disrupted by freeze-thaw method. The cytosolic extract was centrifuged at 14,000× g for 10 min 
at 4 °C and the supernatant was used for SOD assay as well as total protein concentration determination 
as previously described [31]. Analyses of all samples were performed within 1 month of collection. 
4.4. Measurement of Plasma Pentosidine 
Plasma pentosidine was measured with sandwich ELISA standard kit (USCNK Life Science Inc., 
Wu Han, China), according to the manufacturer’s protocol. The plate was coated with monoclonal 
antibody against human pentosidine and a polyclonal antibody was used for detection. Mean minimal 
detectable dose of pentosidine was 0.087 ng/mL. Results were expressed as ng/mL. The inter-assay 
coefficient of variation was 5.1%.  
4.5. Measurement of Plasma sRAGE 
Plasma sRAGE was measured with sandwich ELISA standard kit (Biovendor Laboratorni Medicina 
akciová společnost, Brno, Řečkovice, Czech Republic), according to the manufacturer’s protocol. The 
plate was coated with monoclonal antibody against human sRAGE and a polyclonal antibody was used 
for detection. Mean minimal detectable dose of sRAGE was 19.2 pg/mL. Results were expressed as 
pg/mL. The inter-assay coefficient of variation was 3.6%.  
4.6. Measurement of Plasma AOPP  
The plasma level of AOPP was quantitatively determined by using colorimetric method as 
described previously [32]. Chloramine-T was used as the standard. Results were expressed as μmol/L. 
The inter-assay coefficient of variation was 4.6%.  
4.7. Measurement of Plasma GPx Activity 
The plasma GPx activity was determined using standard kit (EnzyChrom™ GPx, Bioassay 
Systems, Hayward, CA, USA), according to the manufacturer’s protocol. The assay is based on the 
oxidation of NADPH in an enzyme coupled reaction. The linear detection range was 12–300 U/L GPx 
activity. Results were expressed as U/L. The inter-assay coefficient of variation was 5.7%.  
4.8. Measurement of PBMC SOD Activity 
The SOD activity in PBMC was measured using a standard kit (Cayman Chemical Company,  
Ann Arbor, MI, USA), according to the manufacturer’s protocol. The assay kit utilizes a tetrazolium 
salt for detection of superoxide radicals generated by xanthine oxidase and hypoxanthine. It can be used 
to detect all 3 types of SOD (Cu/Zn, Mn, and FeSOD), with dynamic range of 0.025–0.25 units/mL 
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SOD. Cytosol protein concentration was determined as previously described [31] and the SOD activity 
was expressed as U/mg. The inter-assay coefficient of variation was 4.5%.  
4.9. Statistical Analysis 
The continuous variables were checked for normality prior to the statistical analysis. Chi-Square 
test with one degree of freedom (for dichotomous variables) and unpaired t-test (for continuous 
variables) were used for the evaluation of differences between groups. Comparison of subgroups was 
performed with ONE-WAY ANOVA and post hoc test of Tukey’s multiple comparisons. Association 
between parameters was determined by Pearson’s correlation coefficient (r) with Bonferroni 
correction. Logistic regression model was used to estimate the odds ratios (ORs) and 95% confidence 
intervals (CIs) for each risk factor for DR among type 2 DM patients. Statistical significance was set at 
p < 0.05. All data were analyzed using IBM statistical package for the social sciences (IBM-SPSS) 
version 18.0 for Windows (IBM Co., New York, NY, USA). 
5. Conclusions  
In conclusion, this study suggests that sRAGE/pentosidine ratio could serve as a risk factor 
determinant for DR as it has a positive correlation with the severity of type 2 DR. This study also 
provides further evidences for the presence of oxidative stress (decreased GPx, SOD activities and 
increased accumulation of AOPP and pentosidine) in DR patients. The interaction between sRAGE 
and other biomarkers in microvascular injury as well as the pathophysiologic mechanisms involved 
deserve further investigation. 
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